文献速递认知障碍与痴呆

用于选择额颞叶变性亚型的2步脑脊液算法

A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes.
PubMed 文献 · JAMA Neurol · 2018-01-01

该病例对照研究基于宾夕法尼亚大学1992至2016年1796例患者数据库,纳入尸检确诊的散发性额颞叶变性(FTLD)和阿尔茨海默病(AD)队列(n=143)、携带TDP或tau相关突变的额颞叶痴呆(FTD)队列(n=60)以及高度预测FTLD的存活患者队列(n=62),开发基于AD核心脑脊液标志物的2步算法以排除AD病理并区分FTLD-tau与FTLD-TDP。

要点

  • 脑脊液p-tau/Aβ1-42比值在单一神经退行性病理尸检队列中排除AD的AUC为0.98(95%CI 0.96-1.00)。
  • 脑脊液p-tau区分纯FTLD-TDP与纯FTLD-tau的AUC为0.87(95%CI 0.73-1.00)。
  • 该算法在存活患者队列中AUC为0.9(95%CI 0.81-0.99),但在携带致病突变的FTD病例中AUC仅0.58(95%CI 0.38-0.77)。

核心结论

  • 在考虑共病AD和遗传状态的情况下,AD脑脊液核心标志物可用于高特异性体内识别纯FTLD-TDP和FTLD-tau患者。

研究设计与样本

  • 宾夕法尼亚大学的病例对照研究,参与者选自1992至2016年间纳入的1796例具有可用脑脊液的不同神经退行性疾病患者数据库。
  • 纳入三个队列:尸检确诊的散发性FTLD和AD队列(n=143);携带TDP相关或tau相关突变的FTD队列(n=60);高度预测FTLD的存活患者综合征队列(进行性核上性麻痹和FTD-肌萎缩侧索硬化;n=62)。
  • 脑脊液Aβ1-42、总tau和p-tau值使用INNO-BIA AlzBio3(xMAP;Luminex)检测或使用先前验证的算法转化的INNOTEST酶联免疫吸附试验获得。

主要发现

  • 尸检队列包括FTLD-tau(n=27;平均[SD]发病年龄60.8[9.7]岁)、FTLD-TDP(n=13;平均[SD]发病年龄62.4[8.5]岁)、AD(n=89;平均[SD]发病年龄66.5[9.7]岁)和混合FTLD-AD(n=14;平均[SD]发病年龄70.6[8.5]岁)。
  • p-tau/Aβ1-42比值在单一神经退行性病理尸检队列中排除AD病例显示出极好的诊断准确性(AUC 0.98;95%CI 0.96-1.00)。
  • 脑脊液p-tau水平区分纯FTLD-TDP与纯FTLD-tau显示出良好的AUC(0.87;95%CI 0.73-1.00)。
  • 应用基于脑脊液p-tau与Aβ1-42比值和p-tau截断值的算法可良好区分纯FTLD-TDP病例与其余FTLD-tau和混合FTLD病例。
  • 该算法的诊断价值在独立的进行性核上性麻痹和FTD-肌萎缩侧索硬化存活患者队列中得到确认(AUC 0.9;95%CI 0.81-0.99)。

关键数值与推荐

  • p-tau/Aβ1-42比值排除AD病例的AUC为0.98(95%CI 0.96-1.00),基于单一神经退行性病理尸检队列。
  • 脑脊液p-tau区分纯FTLD-TDP与纯FTLD-tau的AUC为0.87(95%CI 0.73-1.00)。
  • 算法在存活患者队列中的AUC为0.9(95%CI 0.81-0.99)。
  • 算法在携带致病突变的FTD病例中的AUC为0.58(95%CI 0.38-0.77)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Cerebrospinal fluid (CSF) core Alzheimer disease (AD) biomarkers have shown an excellent capacity for the in vivo detection of AD. Previous studies have shown that CSF levels of phosphorylated tau (p-tau) also correlate with tau pathology in frontotemporal lobar degeneration (FTLD) after accounting for AD copathology. OBJECTIVE: To develop an algorithm based on core AD CSF measures to exclude cases with AD pathology and then differentiate between FTLD-tau and FTLD transactive response DNA-binding protein of approximately 43kDa (FTLD-TDP). DESIGN, SETTING, AND PARTICIPANTS: A case-control study at the University of Pennsylvania. Participants were selected from a database of 1796 patients included between 1992 and 2016 with different neurodegenerative diseases with available CSF. Three patient cohorts were included: a cohort of patients with sporadic, autopsy-confirmed FTLD and AD (n = 143); a cohort of patients with frontotemporal degeneration (FTD) with TDP-associated or tau-associated mutations (n = 60); and a living cohort of patients with syndromes highly predictive of FTLD (progressive supranuclear palsy and FTD-amyotrophic lateral sclerosis; n = 62). MAIN OUTCOMES AND MEASURES: Cerebrospinal fluid values of amyloid β1-42 (Aβ1-42), total tau (t-tau), and p-tau obtained using the INNO-BIA AlzBio3 (xMAP; Luminex) assay or INNOTEST enzyme-linked immunosorbent assay transformed using a previously validated algorithm. Sensitivities and specificities for differentiating AD from FTLD groups were calculated. RESULTS: This autopsy cohort included FTLD-tau (n = 27; mean [SD] age at onset, 60.8 [9.7] years), FTLD-TDP (n = 13; mean [SD] age at onset, 62.4 [8.5] years), AD (n = 89, mean [SD] age at onset, 66.5 [9.7] years); and mixed FTLD-AD (n = 14, mean [SD] age at onset, 70.6 [8.5] years).The p-tau/Aβ1-42 ratio showed an excellent diagnostic accuracy to exclude AD cases in the autopsy cohort with single neurodegenerative pathologies (area under the curve [AUC], 0.98; 95% CI, 0.96-1.00). Cerebrospinal fluid p-tau levels showed a good AUC (0.87; 95% CI, 0.73-1.00) for discriminating pure FTLD-TDP from pure FTLD-tau. The application of an algorithm using cutpoints of CSF p-tau to Aβ1-42 ratio and p-tau allowed a good discrimination of pure FTLD-TDP cases from the remaining FTLD-tau and mixed FTLD cases. The diagnostic value of this algorithm was confirmed in an independent cohort of living patients with progressive supranuclear palsy and FTD-amyotrophic lateral sclerosis (AUC, 0.9; 95% CI, 0.81-0.99). However, the algorithm was less useful in FTD cases carrying a pathogenic mutation (AUC, 0.58; 95% CI, 0.38-0.77) owing to elevated p-tau levels in TDP-associated mutation carriers. CONCLUSIONS AND RELEVANCE: Alzheimer disease CSF core biomarkers can be used with high specificity for the in vivo identification of patients with pure FTLD-TDP and FTLD-tau when accounting for comorbid AD and genetic status.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Lleó A, Irwin DJ, Illán-Gala I, et al. A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes. JAMA Neurol. 2018. PMID: 29554190. doi:10.1001/jamaneurol.2018.0118

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。